Experimental Pill Daraxonrasib Shows Promise in Extending Survival for Pancreatic Cancer Patients
A new experimental drug, daraxonrasib, has shown promising results in extending the survival of patients with advanced pancreatic cancer. According to a study presented at the American Society for Clinical Oncology meeting, the drug targets a mutated protein that promotes tumor growth in over 90% of pancreatic cancer cases. In a trial involving 500 patients, those who received daraxonrasib lived a median of 13.2 months compared to 6.7 months for those on chemotherapy. The drug, which is taken as a daily pill, also resulted in fewer severe side effects and improved quality of life for patients. The study's findings were published in the New England Journal of Medicine, and the drug's development is funded by Revolution Medicines. 
